AONC Quote, Financials, Valuation and Earnings

Pediatrix Medical Group, Inc. has a net margin of -0.23% compared to American Oncology Network, Inc.'s net margin of 14.55%. American Oncology Network, Inc.'s return on equity of -13.79% beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

American Oncology Network, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could grow by 3.55%. Given that Pediatrix Medical Group, Inc. has higher upside potential than American Oncology Network, Inc., analysts believe Pediatrix Medical Group, Inc. is more attractive than American Oncology Network, Inc..

American Oncology Network, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.766, suggesting its less volatile than the S&P 500 by 23.447%.

American Oncology Network, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. American Oncology Network, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

American Oncology Network, Inc. quarterly revenues are $470.3M, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. American Oncology Network, Inc.'s net income of -$1.1M is lower than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, American Oncology Network, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 11.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for American Oncology Network, Inc. is 0.15x versus 0.97x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of -0.23% compared to American Oncology Network, Inc.'s net margin of -22162.75%. American Oncology Network, Inc.'s return on equity of -13.79% beat Kindly MD, Inc.'s return on equity of -91.57%.

American Oncology Network, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 234.58%. Given that Kindly MD, Inc. has higher upside potential than American Oncology Network, Inc., analysts believe Kindly MD, Inc. is more attractive than American Oncology Network, Inc..

American Oncology Network, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

American Oncology Network, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. American Oncology Network, Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.

American Oncology Network, Inc. quarterly revenues are $470.3M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. American Oncology Network, Inc.'s net income of -$1.1M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, American Oncology Network, Inc.'s price-to-earnings ratio is -- while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for American Oncology Network, Inc. is 0.15x versus 10.47x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SRx Health Solutions, Inc. has a net margin of -0.23% compared to American Oncology Network, Inc.'s net margin of -13.47%. American Oncology Network, Inc.'s return on equity of -13.79% beat SRx Health Solutions, Inc.'s return on equity of --.

American Oncology Network, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that American Oncology Network, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe American Oncology Network, Inc. is more attractive than SRx Health Solutions, Inc..

American Oncology Network, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.069%.

American Oncology Network, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. American Oncology Network, Inc. pays -- of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend.

American Oncology Network, Inc. quarterly revenues are $470.3M, which are larger than SRx Health Solutions, Inc. quarterly revenues of $7.2M. American Oncology Network, Inc.'s net income of -$1.1M is lower than SRx Health Solutions, Inc.'s net income of -$964K. Notably, American Oncology Network, Inc.'s price-to-earnings ratio is -- while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for American Oncology Network, Inc. is 0.15x versus 0.04x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of -0.23% compared to American Oncology Network, Inc.'s net margin of -10.08%. American Oncology Network, Inc.'s return on equity of -13.79% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

American Oncology Network, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 78.08%. Given that The Oncology Institute, Inc. has higher upside potential than American Oncology Network, Inc., analysts believe The Oncology Institute, Inc. is more attractive than American Oncology Network, Inc..

American Oncology Network, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.817%.

American Oncology Network, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. American Oncology Network, Inc. pays -- of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend.

American Oncology Network, Inc. quarterly revenues are $470.3M, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. American Oncology Network, Inc.'s net income of -$1.1M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, American Oncology Network, Inc.'s price-to-earnings ratio is -- while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for American Oncology Network, Inc. is 0.15x versus 0.68x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.